Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …

Glucagon-like peptide-1 (GLP-1), is a hormone secreted by small intestine. Consumption of
food or glucose stimulates synthesis and secretion of GLP-1 in the bloodstream, which in …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Abstrat Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in
response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Type 2 diabetes mellitus is a major and growing health problem throughout the world.
Current treatment approaches include diet, exercise, and a variety of pharmacological …

Type 2 diabetes has been identified as a risk factor for Alzheimer's disease (AD). The
underlying mechanism behind this unexpected link is most likely linked to the observed …

In the past few years, the development of pharmaceutical agents that enhance the
physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor …

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …